drugset / Trial / NCT00595426

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

NCT00595426

Phase 2 Completed 685 enrolled Astellas Pharma Inc
RandomizedParallel-groupDouble-blindPrevention

Summary

To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery

Timeline

Start
2008-05
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Warfarin Small molecule Oral
Subject darexaban Small molecule Oral

Indications